

## Isabel Hershey

**From:** Gazella, Patricia A. (SLU) <patti\_gazella@express-scripts.com>  
**Sent:** Wednesday, September 14, 2016 11:36 AM  
**To:** Gazella, Patricia A. (SLU)  
**Subject:** Annual Formulary Update: 2017 Status Changes



## Annual Formulary Update: 2017 Status Changes

Express Scripts recently completed its annual formulary review. This communication describes the drug list changes that will go into effect for your member population on Jan. 1, 2017. As always, our formulary development process calls for a focus on clinical factors, with financial considerations coming into play only among clinically comparable or optional products.

Our formulary is designed to bring the greatest value to you and your members while increasing your population's use of the lowest net-cost products. Over the past three years, our formulary management strategy has maintained broad drug access with minimal member disruption while maximizing your ability to control costs. As we head into 2017, we continue our momentum by delivering more savings with minimal member impact, ensuring you achieve optimal results from your pharmacy benefit.

### Summary of 2017 Changes

The new exclusions in our 2017 National Preferred Formulary will impact approximately 0.08% of our members while continuing to add value for you. Member impact specific to your plan is available upon request. Our formulary will continue to ensure that clinically sound, cost-effective drugs are available to members and will drive greater savings, in part by minimizing brand inflation and by reducing the use of non-preferred brands. A summary of changes is below, and the complete list of 2017 exclusions and available preferred alternatives is available [here](#).

| New Exclusions |         |         |
|----------------|---------|---------|
| COLCHICINE     | KINERET | ORENCIA |
| TALTZ          | ZYCLARA |         |

| Preferred-to-Nonpreferred Changes       |                                            |           |
|-----------------------------------------|--------------------------------------------|-----------|
| ACCU-CHEK COMPACT BLUE CONTROL SOLUTION | ANALPRAM ADVANCED, ANALPRAM-HC 2.5% LOTION | CUPRIMINE |
| DIFFERIN 0.1% LOTION                    | FORADIL                                    | LIPTRUZET |
| MIRAPEX ER 3.75 MG TABLET               | OXTELLAR XR                                | RIOMET    |
| TRELSTAR LA                             | XTANDI                                     | DAKLINZA* |

\* Note: These products are currently excluded on NPF, but members who meet the exception criteria for coverage will experience a preferred-to-nonpreferred copay change.

### **Comprehensive Communication Plan Minimizes Disruption**

Our goal is to make each impacted member's experience as smooth as possible. Beginning this fall, we will notify members, physicians and pharmacists of these formulary changes to ensure clear communication. Member communications include the following:

1. Personalized notifications and reminder communications will be sent to affected members before Jan. 1. These notifications will include a list of alternative medications and information for facilitating conversion to a preferred product.
2. Targeted email communications, an educational video and Express-Scripts.com will provide additional information about preferred options and generic alternatives.
3. Throughout 2017, members who attempt to fill an excluded product will receive a targeted alert.

I also can provide an interactive member, physician and pharmacist notification timeline, as well as information that you can include in communications to your population.

### **Continuing Formulary Success**

We conduct reviews of exclusion therapy classes on an ongoing basis. Express Scripts' proven approach to formulary management allows us to address high-cost drugs as they come to market, without making plan sponsors wait and foot the bill until the next calendar year. With our unmatched expertise and scale, we are uniquely positioned to manage the formulary in such a way that we ensure positive patient experiences and drive better outcomes. In 2017, this approach will save our clients \$1.8 billion.

No action is required from you. Please contact me with any questions or for more information. As always, we greatly value our relationship and look forward to continuing to serve you and your members.

Thank you,  
<First and Last Name>  
<Phone Number>  
<Title>  
Express Scripts